Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy

Area of Science:

• Molecular Biology
• Genetics
• RNA Therapeutics

Background:

• Myotonic dystrophy type 1 (DM1) is a genetic disorder caused by expanded CTG repeats in the DMPK gene.
• Toxic RNA foci sequester RNA-binding proteins like Muscleblind-like proteins (MBNLs), disrupting RNA metabolism and causing disease.
• Current therapeutic strategies for DM1 are limited.

Purpose of the Study:

• To investigate the therapeutic potential of very short, chemically modified antisense oligonucleotides composed exclusively of locked nucleic acids (all-LNAs).
• To assess the efficacy of all-LNAs in targeting CUG repeat expansions and restoring normal RNA processing in DM1 models.

Main Methods:

• Designed and synthesized 8- or 10-unit all-LNAs complementary to CUG repeats.
• Evaluated in vitro binding affinity of all-LNAs to CUG repeat RNA.
• Assessed the effect of all-LNAs on CUG(exp)/MBNL complex formation in DM1 cells and a DM1 mouse model.
• Analyzed the reduction of nuclear foci, correction of alternative splicing defects, and impact on overall transcript levels.

Main Results:

• All-LNAs effectively bound CUG repeat RNA and prevented the formation of toxic CUG(exp)/MBNL complexes.
• In DM1 cells and mouse models, all-LNAs significantly reduced the number and size of CUG(exp) nuclear foci.
• All-LNAs demonstrated high efficacy and specificity in correcting MBNL-sensitive alternative splicing defects.
• The treatment showed minimal impact on the cellular levels of toxic transcripts and did not affect other transcripts.

Conclusions:

• Very short all-LNAs are a promising therapeutic tool for myotonic dystrophy type 1.
• These oligonucleotides offer a targeted approach to reduce toxic RNA accumulation and restore normal cellular function in DM1.
• The specificity and efficacy observed suggest potential for clinical development in DM1 treatment.